Introduction
============

The Centers for Disease Control and Prevention (CDC) and many public health jurisdictions continue to advocate for the most sensitive rapid HIV test that is available, both to identify positive patients when they are at their most infectious, and to ensure that negative patients are truly negative when starting a pre-exposure prophylaxis regimen ([@ref-1]). Currently, the recommendation is to utilize tests that can detect HIV infection biomarkers within 30 days of infection, when initial immune responses are mounted. Typically, these biomarkers measure the presence of virus, such as p24 antigen or viral RNA, the patient's IgM and IgG immune response to HIV infection, and/or the level of CD4 T cells (see [Fig. 1](#fig-1){ref-type="fig"}).

![Various biomarkers utilized for HIV detection.\
Stages of HIV life cycle (Fiebig stages) and relative abundance of biomarkers throughout these stages. Different biomarkers allow for detection of infection at different stages, represented by the boxes and labels below the chart. This figure is adapted from [@ref-6].](peerj-06-4430-g001){#fig-1}

The CDC and the Association of Public Health Laboratories (APHL) have issued revised recommendations ([@ref-1]) based on HIV tests approved by the Food and Drug Administration (FDA). The CDC and APHL recommend that laboratories use an automated, laboratory-based p24 antigen/antibody HIV screening immunoassay followed, if reactive, by an HIV-1/HIV-2 antibody differentiation immunoassay. When the differentiation assay interpretation is negative or indeterminate for HIV-1, an HIV-1 nucleic acid test (NAT) is recommended (see [Fig. 2](#fig-2){ref-type="fig"}).

![Centers for disease control and prevention HIV testing algorithm.\
Reproduced from laboratory testing for the diagnosis of HIV infection: updated recommendations, 2014.](peerj-06-4430-g002){#fig-2}

For those settings where an automated laboratory instrument is not available or serum/plasma sample collection is not practical or cost-effective to utilize, a separate guideline for testing in non-clinical settings has been established ([@ref-2]). These guidelines recommend that sites use HIV testing technologies that are the most sensitive, cost-effective, and feasible for use by their agency.

Rapid, POC testing is a logical choice for screening in a non-clinical setting. It is important, for the reasons outlined above, that a POC test is still able to detect infection within the 30-day acute infection window period. The only way that this can occur is by the detection of either the IgM antibody response or p24 antigen ([@ref-6]). While there is an FDA-approved POC test that detects p24 antigen available today, numerous data has been presented and published showing limited utility of p24 detection in fingerstick whole blood samples due to low sensitivity of the device in the 20--50 pg/ml range compared to automated p24/IgM/IgG assays with sensitivity as low as 0.1 pg/ml ([@ref-13]; [@ref-5]; [@ref-7]). This lack of sensitivity drives the market towards POC tests that detect IgM antibodies.

A recent study has demonstrated that POC tests using a Protein A-based detection system can detect samples with predominantly HIV-1 IgM reactivity ([@ref-9]). The OraQuick *ADVANCE*® Test also uses Protein A as the detection protein in the antibody-binding colloidal gold conjugate. Due to this, it is expected that the OraQuick *ADVANCE*® Test will also detect samples with predominantly IgM reactivity.

The OraQuick *ADVANCE*® Test has proven performance and patient acceptability that is facilitated by specimen flexibility ([@ref-18], [@ref-12], [@ref-11]; [@ref-19], [@ref-15], [@ref-10]; [@ref-8]). The OraQuick *ADVANCE*® Test is a simple, three-step protocol providing results in 20 minutes. The test is FDA-approved with \>99% sensitivity and specificity claimed across many specimen types, including oral fluid, fingerstick blood and whole blood. FDA approval for the OraQuick *ADVANCE*® Test using oral fluid as the specimen type was in 2004, and raw material and manufacturing process changes that allowed earlier detection of seroconversion was FDA approved in 2015.

This report describes the results of a study designed to evaluate the seroconversion performance of the OraQuick *ADVANCE*® Test compared to automated IgG/IgM enzyme immunoassay (EIA) performance and to confirm the hypothesis that its Protein A-based detection system is able to detect samples known to be predominantly IgM positive, thereby demonstrating it is appropriate as a POC diagnostic test for acute HIV infection.

Materials and Methods
=====================

OraQuick *ADVANCE*® Rapid HIV-1/2 Antibody Test
-----------------------------------------------

The OraQuick *ADVANCE*® Test is FDA approved to detect antibodies to human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) in whole blood (from a fingerstick or venipuncture sample), plasma, or oral fluid sample. The assay strip in the device consists of a membrane of nitrocellulose striped with control and test lines. The test line is striped with both HIV-1 and HIV-2 synthetic peptides and modified streptavidin (a biotin-binding protein). HIV-specific antibodies are introduced with the sample, and, if present, will interact with biotinylated HIV-1 and HIV-2 peptides and colloidal gold labeled with Protein A, which are impregnated in different sections of the device. This sample-reagent mixture then flows up the nitrocellulose, with complexed gold particles binding to the test line components in various "sandwich" configurations ([Fig. 3](#fig-3){ref-type="fig"}).

![Operating principle of the OraQuick *ADVANCE*® Test.\
Sample is wicked up the device, hydrating blocker and conjugate pad reagents, which are transferred to the nitrocellulose membrane. HIV antibodies in the sample bind biotinylated reagents and are labeled by Protein A colloidal gold. The immuno-sandwich is immobilized by biotin binding with Streptavidin-BSA, and by anti-HIV antibodies interacting with anchored peptides at the test line. Human antibodies complexed with Protein A colloidal gold are captured at the control line. Accumulation of colloidal gold at the control and test lines creates a reddish-purple stripe.](peerj-06-4430-g003){#fig-3}

The presence of HIV-1 and/or HIV-2 antibodies in the tested specimen is indicated by the appearance of a reddish-purple colored band at the test line location of the device within 20--40 minutes.

Comparison of seroconversion detection by OraQuick *ADVANCE*® Rapid HIV-1/2 Antibody Test to IgG/IgM automated assays
---------------------------------------------------------------------------------------------------------------------

The performance of three independent production lots of the OraQuick *ADVANCE*® Test (lot numbers 15070PL0, 6650009, and 6650592) was evaluated across 201 samples from 23 different commercially available seroconversion panels ([Table 1](#table-1){ref-type="table"}), as described in the package insert. Each panel consists of sequential plasma specimens obtained from a single HIV-infected individual during seroconversion. Five microliters of each seroconversion panel member was spiked into developer solution and three replicates were run per panel member for each lot. Results were read after a 20 minute incubation period. The results were compared to those provided by the seroconversion panel vendor, which were determined using FDA-approved automated IgG/IgM assays.
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###### Commercially available seroconversion panels used in analysis of seroconversion sensitivity for the OraQuick *ADVANCE*® test.
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  Vendor        Panel name   Panel number(s)
  ------------- ------------ -----------------
  SeraCare      PRB924       1--8
  SeraCare      PRB925       1--6
  SeraCare      PRB926       1--6
  SeraCare      PRB933       1--3
  SeraCare      PRB934       1--3
  SeraCare      PRB939       1--9
  SeraCare      PRB945       1--6
  SeraCare      PRB947       1--4
  SeraCare      PRB959       1--7
  SeraCare      PRB965       1--6
  SeraCare      PRB967       1--6
  SeraCare      PRB968       1--10
  SeraCare      PRB969       1--10
  SeraCare      PRB970       1--4
  ZeptoMetrix   6243         1--10
  ZeptoMetrix   9015         1--10
  ZeptoMetrix   9019         1--3
  ZeptoMetrix   9032         1--14
  ZeptoMetrix   9076         1--10
  ZeptoMetrix   9077         1--29
  ZeptoMetrix   9079         1--25
  ZeptoMetrix   9084         1--4
  ZeptoMetrix   12008        1--13

Detection of IgM antibodies
---------------------------

A previous study characterized samples in commercially available seroconversion panels as containing detectable levels of either IgG-only, IgG and IgM, or IgM-only by depleting all IgM antibodies from the sample then testing with a reference ELISA and a POC antibody test ([@ref-9]). Due to limited sample availability from the vendor, 15 of the 20 samples identified as being predominantly IgM (greater than 50% of total immunoglobulin content) were utilized in this study. These samples were tested concurrently with the OraQuick *ADVANCE*® Test, and the INSTI® HIV-1/HIV-2 antibody test (INSTI™; bioLytical Laboratories, Richmond, BC, USA) as described in the original report ([@ref-9]), following the package insert in each case.

In this study, these samples were evaluated using the OraQuick *ADVANCE*® Test by spiking 5 microliters of each sample into developer solution. The device was read after a 20 minute incubation period as per the package insert. The INSTI® assay required 50 microliters of sample and the protocol was followed as per the package insert.

Results
=======

Comparison to IgG/IgM automated assays
--------------------------------------

A total of 201 panel members were tested across the 23 seroconversion panels. Each panel member was run in triplicate and a result was determined to be positive with the presence of a complete test line at or above the limit of visual detection in all three replicates (see [Table 2](#table-2){ref-type="table"}). The average performance of the OraQuick *ADVANCE*® Test was compared to the automated EIA data reported in the seroconversion package inserts. Thirteen of the 23 panels had data reported from more than one EIA platform, and in these cases the average of the two or three results was used to compare to the OraQuick *ADVANCE*® Test results. A total of 114 of the 201 panel members tested negative for both EIA and in all three lots of the OraQuick *ADVANCE*® Test. When comparing the overall average of seroconversion detection days after first bleed for EIA to the three lot average, the OraQuick *ADVANCE*® Test detected seroconversion within 1.5 days of the automated IgG/IgM assays (95% CI \[−0.1 to 3.1 days\]), with three panels being detected earlier by the OraQuick *ADVANCE*® Test, seven on the same day and 13 later.
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###### Comparison of HIV seroconversion detection between three lots of the OraQuick *ADVANCE*® HIV Test and automated enzyme immunoassay (EIA) tests.

![](peerj-06-4430-g005)

  Panel                                                Days after initial bleed   Days OraQuick *ADVANCE* average--EIA average                                                                                         
  ---------------------------------------------------- -------------------------- ---------------------------------------------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -------- ---------
  924                                                  35                         40                                             35         37         33                                                     33       3.7
  925                                                  44                         44                                             44         44         44                               49                    46.5     −2.5
  926                                                  27                         27                                             27         27         27                               27                    27       0.0
  933                                                  27                         27                                             27         27         21                               27                    24       3.0
  934                                                  7                          7                                              7          7          7                                11                    9        −2.0
  939                                                  103                        103                                            103        103        103                              103                   103      0.0
  945                                                  20                         20                                             20         20         13                                                     13       7.0
  947                                                  11                         20                                             20         17         9                                20                    14.5     2.5
  959                                                  14                         14                                             14         14         9                                14                    11.5     2.5
  965                                                  12                         12                                             12         12         12                                                     12       0.0
  967                                                  19                         19                                             19         19                                                     17         17       2.0
  968                                                  33                         33                                             33         33                                                     26         26       7.0
  969                                                  70                         70                                             70         70                                                     70         70       0.0
  970                                                  14                         14                                             14         14                                                     10         10       4.0
  6243                                                 32                         32                                             32         32                    32         32                               32       0.0
  9015                                                 35                         35                                             35         35         35                               37         30         34       1.0
  9019                                                 38                         38                                             38         38         38                               38         38         38       0.0
  9032                                                 36                         36                                             36         36         24                               51         29         34.7     1.3
  9076                                                 74                         69                                             69         71         66                                          66         66       4.7
  9077                                                 45                         45                                             45         45         57                                          52         54.5     −9.5
  9079                                                 55                         55                                             55         55         47                                          47         47       8.0
  9084                                                 49                         49                                             49         49         49                                                     49       0.0
  12008                                                33                         35                                             35         34         33                                          33         33       1.3
  **Average**                                          **36.2**                   **36.7**                                       **36.5**   **36.5**   **34.8**   **32.0**   **32.0**   **37.7**   **38.0**   **35**   **1.5**
  **OQ average for equivalent samples**                **37.3**                   **32.0**                                       **32.0**   **34.8**   **40.9**                                                        
  **OQ average--EIA average for equivalent samples**   **2.4**                    **0.0**                                        **0.0**    **−2.9**   **2.9**                                                         

Detection of IgM antibodies
---------------------------

Among the 15 samples that were characterized as either IgM-only or predominantly IgM ([Table 1](#table-1){ref-type="table"}), 14 of 15 were detectable by both the OraQuick *ADVANCE*® test and INSTI™ ([Table 3](#table-3){ref-type="table"}). As these samples were shown previously to be reactive ([@ref-9]), any sample that was initially non-reactive was repeated in triplicate to confirm the result. The one sample not detected by the OraQuick *ADVANCE*® Test was 943-06 (IgM-only), and the one sample not detected by INSTI® was 938-03 (IgM-only). One sample (950-04---predominantly IgM) was initially scored as non-reactive with the OraQuick *ADVANCE*® Test, but was positive in all three confirmatory tests.
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###### Detection of predominantly IgM or IgM-only samples by the OraQuick *ADVANCE*® Test and INSTI® test.
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  Panel name sample   Panel number   \% IgM in sample (%)   OraQuick *ADVANCE*® Rapid HIV-1/2 Antibody Test   INSTI® HIV-1/2 antibody test
  ------------------- -------------- ---------------------- ------------------------------------------------- ------------------------------
  PRB914              1              100                    R                                                 R
  PRB914              2              \>50                   R                                                 R
  PRB914              3              100                    R                                                 R
  PRB924              8              \>50                   R                                                 R
  PRB925              5              100                    R                                                 R
  PRB925              6              \>50                   R                                                 R
  PRB927              3              \>50                   R                                                 R
  PRB928              2              100                    R                                                 R
  PRB934              2              \>50                   R                                                 R
  PRB934              3              \>50                   R                                                 R
  PRB938              3              100                    R                                                 NR
  PRB940              4              \>50                   R                                                 R
  PRB943              6              100                    NR                                                R
  PRB944              5              100                    R                                                 R
  PRB950              4              \>50                   R                                                 R

**Note:**

Seroconversion panel members from SeraCare were previously determined to have predominantly IgM or IgM-only HIV antibodies ([@ref-9]). Samples were tested with OraQuick *ADVANCE*® and INSTI® tests and reactivity recorded.

Discussion
==========

The revised HIV testing recommendations published by the CDC and APHL in June, 2014 have focused testing on early detection during the acute phase of infection ([@ref-1]). Lab-based tests typically use automated p24 antigen/antibody HIV screening immunoassays followed, if reactive, by an HIV-1/HIV-2 antibody differentiation immunoassay. The ability to detect p24 antigen and/or IgM allows these assays to detect the acute phase of infection when patients are most infectious.

It is well established that persons at high risk for HIV infection, such as gay and bisexual males, injection drug users, and minority populations have a history of not engaging in routine care for a variety of system, social and individual factors ([@ref-14]). For these populations, as well as those in rural settings, rapid POC HIV diagnostics have been shown to help identify undiagnosed infections and increase screening in all levels of the healthcare system and outreach programs ([@ref-17]). It is important that these more convenient tests are also able to detect acute infections, either by p24 antigen or IgM antibody detection.

The performance of the OraQuick *ADVANCE*® Test has been established in clinical population settings to support CE approval in Europe, FDA approval in the US and PreQualification by the World Health Organization. The purpose of the study reported here was to evaluate the ability of the OraQuick *ADVANCE*® Test to (i) detect seroconversion of plasma panels collected from HIV-infected subjects compared to automated lab-based IgM/IgG assays, and (ii) detect HIV antibodies in plasma samples that contain predominantly IgM antibodies to HIV. It is noted that the authors are not aware of any attempts to replicate these results by others.

The results shown in [Table 2](#table-2){ref-type="table"} demonstrate that the OraQuick *ADVANCE®* Test is able to detect seroconversion an average of 1.5 days earlier than automated assays. While there were differences between platforms, with average differences ranging from 2.9 days earlier (Genetic Systems, Redmond, WA, USA) to 2.9 days later (BioRad, Hercules, CA, USA), 10 of the 23 panels detected seroconversion with the OraQuick *ADVANCE*® Test at the same time or earlier than the automated assays.

It is possible that these panels, and others, would be detected sooner with a test that also includes p24 antigen detection, which highlights a known limitation of antibody-only testing platforms. However, as described above, the only FDA-approved rapid test with p24 antigen does not have sufficient sensitivity in fingerstick whole blood applications ([@ref-16]), which is preferred for blood-based testing in non-clinical settings, and drives the POC market towards tests that detect IgM antibodies.

Testing of 15 seroconversion samples that were previously characterized ([@ref-9]) as containing predominantly IgM antibodies with the OraQuick *ADVANCE*® Test and INSTI® demonstrated both tests are able to detect IgM antibodies, with each device detecting 14 of 15 predominantly IgM samples, although each failed to detect different samples ([Table 3](#table-3){ref-type="table"}).

Conclusion
==========

The results of this study demonstrate that the OraQuick *ADVANCE*® Test can detect IgM antibodies during an acute infection window period. Based on this capability it can be inferred that the test is able to detect seroconversion approximately 20--25 days after infection, and is therefore suitable for use in testing environments requiring adherence to the CDC and APHL recommendations.
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